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N-Myristoylglutamic Acid Derivative of 3′-Fluoro-3′-
Deoxythymidine as an Organogel
Bhupender S. Chhikara, Rakesh Tiwari, and Keykavous Parang*
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston,
Rhode Island, 02881, USA
Abstract
Designing microbicidal gels of anti-HIV drugs for local application to prevent HIV infection is a
subject of major interest. 3′-Fluoro-3′-deoxythymidine (FLT), a nucleoside reverse transcriptase
inhibitor (NRTI), was conjugated with a N-myristoyl glutamate scaffold. The conjugate showed
gelation at 1% (w/w) in different organic solvents, such as toluene, dichloromethane, and
chloroform. The gels were opaque and stable at room temperature. The results indicate that
myristoyl glutamate derivative of FLT can form an organogel. The gel could have potential
application as a topical anti-HIV microbicidal agent.
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Nucleoside analogues have been widely used for the treatment of different cancers1–3 and
human immunodeficiency virus (HIV) infection.4 Nucleoside reverse transcriptase inhibitors
(NRTIs) are the main class of anti-HIV drugs. Reverse transcriptase is an enzyme involved
in RNA to DNA conversion in the HIV-infected cells.5 NRTIs are used in combination with
other drugs in highly active antiretroviral therapy (HAART).
HIV is mainly transmitted through sexual interactions, Therefore, there is an urgent need to
develop safe and effective preventative strategies.6 Microbicides are topically applied agents
that prevent or reduce transmission of infectious diseases, in particular HIV infection.7 The
topical microbicides are expected to be biocompatible, broad-spectrum, potent nontoxic,
lacking detergent-type membrane toxicity, being harmless to the mucosal microflora, and to
display broad-spectrum activity against drug-resistant HIV.
NRTIs are very polar compounds and may not be easily applicable as topical microbicides.
Thus, it is important to convert the drug to a suitable form for topical applications. The gel
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form of drugs or drugs incorporated in gels8 are one of the most convenient forms that have
found application in diverse fields, including drug delivery.9
Organogels are semi-solid formulations with an organic liquid phase is trapped by a three-
dimensional network composed of self-assembled fibers. A number of organogelators have
been reported for drug delivery application, such as lecithin, glyceryl fatty acid esters,
poly(ethylene), N-lauroyl-glutamic acid di-n-butylamide, and N-stearoyl alanine methyl
ester, mostly for dermal and transdermal formulations.9 Herein, we report the gel formation
by conjugation of a model nucleoside analogue, 3′-fluoro-2′,3′-dideoxythymidine (FLT) as
a NRTI,10 and a lipophilic myristoylated glutamic acid as organogelator. To the best of our
knowledge, this is the first report of designing a gel by synthesizing lipophilic nucleoside-
glutamic acid derivatives.
The glutamic acid-nucleoside conjugate derivative was synthesized starting from
Glu(OtBu)-OH (1) (Scheme 1). The myristoyl group was coupled to 1 by reaction with
myristic anhydride in the presence of N,N-diisopropylethylamine (DIPEA) to yield
myristoylated glutamic acid (N-My-Glu(OtBu)-OH, 2). Conjugation of 2 with FLT in the
presence of 1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), DIPEA, and
hydroxybenzotriazole (HOBt) afforded N-My-Glu(OtBu)-OFLT (3). HOBt was used to
protect the racemization of glutamic acid. Deprotection of tBu in 3 was accomplished in the
presence of TFA/DCM (95:5 v/v) to yield My-Glu(OH)-OFLT (4). The direct hydrolysis of
myristoylated t-butylglutamic acid (2) with 95% TFA solution in DCM (v/v) gave N-
myristoylglutamic acid (5, N-My-Glu-OH).
The gelation properties of the synthesized derivatives 4 and 5 were evaluated by dissolving
them in different solvents at 1% w/w ratio, three times repeated treatment of heating the
mixture to 45 °C and sonication in a water bath sonicator for 5 minutes, followed by keeping
the solution stable at room temperature for overnight.
The gelation of compounds 4 and 5 was evaluated in different solvents by a similar
procedure and under similar conditions. As shown in Figure 1, N-myristoylated glutamate
derivative of FLT 4 formed the white opaque gel in dichloromethane and toluene while the
control N-myristoylated glutamic acid 5 did not form any gel under similar conditions.
These data suggest that the presence of FLT is required for gel formation. The details of the
gel formation in different solvents are shown in Table 1.
Furthermore, UV studies were conducted to find the solution to gel and gel to solution phase
transition temperature in CHCl3 solution. The cooling scan of the solution of compound 4 in
chloroform from 50 °C to 5 °C followed by heating scan from 5 °C to 50 °C was monitored
by change in UV absorbance at 265 nm (Figure 2). The cooling scan graph on extrapolation
of change on absorption pattern with temperature change gave the phase transition between
30–35 °C. The graph pattern was different during the heating scan and showed
comparatively higher absorption or non-transmittance of light probably due to the presence
of opaque gel form. There was a significant change in absorption graph from 35–40 °C,
indicative of phase transition in this range. These data suggest the formation of low
molecular weight organogel that is stabilized by weak inter-chain interactions. In non-
aqueous conditions, the major attractive forces are possibly hydrogen bonding between
glutamate amides, hydrogen bonding between nucleosides, and van der Waals interactions
between alkyl chains of myristoyl groups. These data are consistent with previously reported
gelation of single-walled carbon nanotubes functionalized with long fatty acyl chain,11
suggesting the potential contribution of van der Waals interactions between alkyl chains for
gel formation.
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An organogel of 4 was generated by dissolving the gelator in toluene and heating. Upon
cooling, the affinity between the gelator and organic solvent decreased leading to self-
assembly into solid aggregates of gelator held through intermolecular interactions.
Transmission electron microscopy (TEM) (Figure 3) showed growth into fibers with 200–
470 nanometers in width and up to several micrometers in length without breakage.
Multidimensional growth pattern suggests a robust morphology.
A number of organogel formulations have been used in drug delivery. For example, lecithin
has been used for the formulation of diclofenac, piroxicam, and indomethacin.7 Most of
these formulations are used for transdermal, rectal, or subcutaneous administration because
this strategy provides a non-invasive mode of administration minimizing the effects of
organic solvents. Transdermal delivery offers net advantages over oral administration in
terms of lowered systemic side effects associated with organic solvents. Gel components
could be chosen according to their compatibility with intended applications, such as using
non-toxic solvents for pharmaceutical applications. It is envisioned that organogel formation
by 4 provides preliminary results for the potential use of nucleoside analogue organogels as
topical anti-HIV microbicide applications. Optimization of the solvents to other nontoxic
solvents and formulations are required to make these organogels appropriate for
pharmaceutical applications. One major advantage of this organogel is that the active
nucleoside pharmaceutical component is a part of gelator and does not need to be mixed
with another drug, avoiding problems associated with the uncontrolled release of drugs from
the formulation. FLT is expected to be released from the conjugate 4 through hydrolysis by
cellular esterase as shown in other ester conjugates of nucleosides.12
In conclusion, the formation of organogels by FLT conjugation with N-myristoyl glutamic
acid was investigated. FLT-myristoyl glutamate conjugate formed organogel in
dichloromethane, toluene, and xylene at 1% w/w. The formed gels were opaque and
remained stable at room temperature. This method can be used for the gelation of other
NRTIs conjugated with N-myristoyl glutamic acid as the organogelator. This organogel
NRTI can be used for the potential application as a topical anti-HIV microbicide. This
strategy presents major advantages as drug delivery formulations, such as ease of
preparation and route of administration.
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Figure 1.
Gelation of compounds 4 and 5 in different solvents (1% w/w). (A) 4 in water (dissolved in
DMSO and then added to water (water:DMSO 100:1 v/v); (B) 4 in methanol; (C) 4 in
CH2Cl2; (D) 4 in toluene; (E) 5 in toluene; (F) 5 in CH2Cl2.
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Figure 2.
UV thermal graph for the compound 4 in CHCl3 with absorbance at 265 nm. (a) Cooling
graph from 50 °C to 5 °C; (b) Heating graph from 5 °C to 50 °C. The reading is average of
three readings for respective graph.
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Figure 3.
TEM of the organogel of 4 in toluene.
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Scheme 1.
Synthesis of N-myristoylglutamic acid derivative of FLT (4) and N-myristoylglutamic acid
(5).
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Table 1
Gel formation by compounds 4 and 5 in different solvents.
Compd. Solvent Gel formation Gel appearance
4 CH2Cl2 Ya Opaque, puff white
4 CHCl3 Y Opaque, puff white
5 CH2Cl2 N Precipitate
5 Methanol N -
4 Methanol N -
4 Toluene Y Opaque, puff white
4 Xylene(s) Y Opaque, puff white
5 Toluene N -
4 Hexane N -
5 Hexane N -
4 Water (DMSO 1% v/v) Nb Precipitate
5 Water N -
4 Ethanol N -
a
Y = Gel formed;
bN = No gel.
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